Table 2 Analysis on relapse-free survival.

From: Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study

 

Landiolol group

Control group

N = 28

N = 29

n (%)

n (%)

Analysis of relapse-free survival

   Event

4 (14.3)

9 (31.0)

   Censor

24 (85.7)

20 (69.0)

   Median [95% CI]a

(−)

(−)

   Log-rank testb

P = 0.1294

 

   Hazard ratioc

0.41

 

   [95% CI]c

[0.13–1.34]

 

   Postoperative relapse-free survival rate at 2 yearsa

0.89

0.75

   [95% CI]a

[0.69–0.96]

[0.55–0.87]

Analysis of postoperative relapse-free survival at 2 yearsd

   Event

3 (10.7)

7 (24.1)

   Censor

25 (89.3)

22 (75.9)

   Postoperative relapse-free survival rate at 2 years

0.89

0.76

   [95% CI]

[0.78–1.01]

[0.60–0.91]

   Chi-squared teste

P = 0.1828

 
  1. Units for duration are months, and 1 month is defined as 30.4375 days.
  2. aEstimated based on Kaplan-Meier method.
  3. b*P < 0.05, N.S.: P ≥ 0.05.
  4. cEstimated based on Cox-Proportional Hazards Model assuming treatment groups to be single factors.
  5. dEvents occurred at least 2 years after surgery in 1 patient in the landiolol group and 2 patients in the control group, and these subjects were handled as not having experienced events.
  6. e*P < 0.05, N.S.: P ≥ 0.05.
Back to article page